Table 3.
LCIG settings and LEDD at baseline and at the patient visit according to duration of LCIG treatment
| Measure | Time point | Time between LCIG initiation and patient visit | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1–2 years n = 156 |
2–3 years n = 80 |
3–4 years n = 61 |
4–5 years n = 30 |
> 5 years n = 60 |
|||||||
| n | Mean ± SD | n | Mean ± SD | n | Mean ± SD | n | Mean ± SD | n | Mean ± SD | ||
| Total LCIG dose (mg) | At LCIG initiation | 155 | 1274.4 ± 524.9 | 80 | 1326.1 ± 480.0 | 60 | 1307.0 ± 487.7 | 30 | 1314.6 ± 628.7 | 60 | 1389.4 ± 392.7 |
| At patient visit | 154 | 1409.8 ± 547.9 | 78 | 1388.8 ± 560.7 | 60 | 1385.6 ± 509.3 | 30 | 1446.4 ± 769.5 | 60 | 1480.9 ± 666.1 | |
| LEDD (mg) | At LCIG initiation | 133 | 2422.3 ± 1033.8 | 64 | 2659.1 ± 1003.9 | 50 | 2647.5 ± 1011.6 | 27 | 2236.8 ± 924.6 | 50 | 2585.5 ± 1034.8 |
| At patient visit | 146 | 2162.4 ± 842.2 | 75 | 2225.7 ± 858.8 | 57 | 2166.5 ± 850.3 | 29 | 2199.3 ± 1098.8 | 55 | 2401.2 ± 1092.1 | |
| n | % | n | % | n | % | n | % | n | % | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Patients on LCIG monotherapy, % | At 12 months after LCIG initiation | 45 | 29.6 | 17 | 22.4 | 19 | 32.2 | 14 | 46.7 | 23 | 39.7 |
| Patients on LCIG monotherapy plus night medication, % | At 12 months after LCIG initiation | 46 | 30.3 | 19 | 25.0 | 15 | 25.4 | 3 | 10.0 | 10 | 17.2 |
| Patients on polytherapy, % | At 12 months after LCIG initiation | 61 | 40.1 | 40 | 52.6 | 25 | 42.4 | 13 | 43.3 | 25 | 43.1 |
LCIG levodopa–carbidopa intestinal gel, LEDD levodopa equivalent daily dose, SD standard deviation